logo
episode-header-image
Sep 2021
18m 26s

Making Sense of Today’s 340B Policy Enta...

Pharmacy Podcast Network
About this episode
Making Sense of Today’s 340B Policy Entanglements As covered entities face rising healthcare costs, reimbursement cuts, and uncompensated care, the Federal 340B Drug Pricing Program continues to be an important source of funding for vital patient care. Get updates on how the 340B program solutions can help providers manage reporting compliance across an incr ... Show More
Up next
Yesterday
Investing in Equity | RxGenius
In this episode of RxGenius, Ryan Paul Liabenow sits down with Jason Torress with Sana Capital. 
45m 45s
Jul 8
LTC Pharmacy at Home; Top 5 Ways to Grow | RxSafe
On episode two of three, we break down the foundations and future of Long-Term Care (LTC) at Home pharmacy services. As aging populations grow and healthcare shifts toward home-based models, independent pharmacies have a major opportunity to lead the way in delivering personalize ... Show More
48m 36s
Jul 2
Whole Planet Care through Herbalism with Richard Mandelbaum | Holistic Pharmacy Podcast
Today I am sharing an important conversation with one of my primary herbal teachers, about the micro and macro views of health and healing. Modern life too often disassociates us from our innate identity and relationship with our greater ecosystem, biome, and planet. Herbal medic ... Show More
48m 21s
Recommended Episodes
Apr 2024
How Hospital Mergers Drive Up Prices for Consumers
P.M. Edition for April 24. A new study found that hospital mergers drive up healthcare costs. The Wall Street Journal’s Melanie Evans discusses how consumers are paying the price. And McKinsey is under criminal investigation for opioid-related consulting services. Plus, major bus ... Show More
13m 46s
Jan 2022
How to thrive in the global wellness market
Read more >    Listen to the podcast (duration: 23:12) >  Consumers everywhere plan to spend more on products and services that improve their health and wellness. Here’s what that means for companies.See www.mckinsey.com/privacy-policy for privacy information 
23m 12s
Sep 2023
Money Talks: The price of cheaper medicines
One of the many aims of President Joe Biden’s signature legislation, the Inflation Reduction Act, is to cut the cost of drugs prescribed by Medicare, a government health insurance programme for Americans 65 and over. But the policy could have some side-effects for patients far be ... Show More
44m 53s
Sep 2023
Money Talks: The price of cheaper medicines
One of the many aims of President Joe Biden’s signature legislation, the Inflation Reduction Act, is to cut the cost of drugs prescribed by Medicare, a government health insurance programme for Americans 65 and over. But the policy could have some side-effects for patients far be ... Show More
44m 53s
Nov 2023
CVS vs. Walgreens | Trouble Behind the Counter | 5
Between overworked pharmacists, healthcare consolidation, and rising drug costs, pharmacies are constantly having to adapt. Dan Weissmann, host of the An Arm and a Leg podcast, joins David to talk about how these conditions are affecting pharmacies — big and small — and consumers ... Show More
42m 21s
Nov 2023
For ACA Plans, It’s Time to Shop Around
It’s Obamacare open enrollment season, which means that, for people who rely on these plans for coverage, it’s time to shop around. With enhanced premium subsidies and cost-sharing assistance, consumers may find savings by switching plans. It is especially important for people wh ... Show More
28m 46s
Aug 2016
Koons on Pfizer Agreeing to Buy Medivation (Audio)
(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. \u0010 \u0010GUEST: \u0010Cynthia Koons \u0010Health Care Reporter \u0010Bloomberg Editorial \u0010on Pfizer beating out rivals to buy biopharmaceutical company, Medivation, and its blockbuster cancer drug for $14 billi ... Show More
7m 19s
Jun 2016
Bloomberg Surveillance: Bloomberg BNA's Eleanor Tyler on pharma
Bloomberg BNA's Eleanor Tyler joins Tom Keene and Mike McKee to discuss pharmaceutical mergeres, tax inversions, drug pricing, and the renewed efforts by the Federal Trade Commission to regulate an increasingly complicated industry. Learn more about your ad-choices at https://www ... Show More
6m 38s
Apr 2024
Money Talks: Why weight-loss drugs will reshape the world
More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ... Show More
36m 59s